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Abstract 
Effects of the anticonvulsant tiagabine in doses of 1, 3 and 10 mg/kg were investigated on electroencephalogram (EEG), 
spike-wave discharges and behaviour of WAG/Rij  rats. These rats are considered as an animal model of generalized, 
non-convulsive, absence pilepsy. WAG/Ri j  rats spontaneously show a considerable number of spike-wave discharges in 
their EEG. These discharges can be facilitated by GABA agonists. The facilitatory effects of these agonists are completely 
opposite to their effects ,an convulsive seizures, which are reduced by these drugs. Tiagabine nhances the effects on the 
GABA system, since it acts as a GABA re-uptake inhibitor. According to expectations, tiagabine nhanced in a dose-related 
way both the number and mean duration of spike-wave discharges. The low dose of 1 mg/kg had almost no effects, but 
doses of 3 and 10 mg/kg were effective. Furthermore, tiagabine in the latter two doses increased the power in the higher 
beta band of the backgrc,und EEG, whereas no significant changes in behavioural parameters were found. An unexpected 
finding was the occurrence of a second type of spike-wave discharges. These were again seen with the two higher doses of 
tiagabine, while 1 mg/kg had no effect. An assumption is that this second type of discharges are forerunners of genuine 
spike-wave discharges. In general, this experiment supports that non-convulsive epilepsy is associated with a GABA 
hyperfunction. It also underlines the biochemical differences of convulsive and non-convulsive animal models of epilepsy. 
Tiagabine, with its GABA-mimetic properties, belongs to the category of drugs effective in convulsive animal models and 
not in non-convulsive models of epilepsy. 
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1. Introduction 
Tiagabine is a recently developed potent and cen- 
trally acting selective GABA-uptake inhibitor. Its 
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anticonvulsant activity is established in several mod- 
els of epilepsy and its anticonvulsant action is al- 
ready effective in doses which do not produce seda- 
tion or motoric side-effects [9]. Tiagabine inhibits the 
re-uptake of GABA in synaptic terminals, implicat- 
ing that it enhances GABA-ergic functions in an 
indirect way [6]. It is generally agreed that GABA 
agonists, such as muscimol, reduce the number of 
seizures in models of convulsive epilepsy and that 
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GABA antagonists, uch as bicuculline and picrotox- 
ine, enhance this type of epilepsy [8,11]. Interest- 
ingly, GABA plays an opposite role in models of 
non-convulsive pilepsy. In rats, spike-wave dis- 
charges of the absence type are facilitated by ago- 
nists and reduced by antagonists [7,12,13,16]. The 
pharmacological difference with respect o the role 
of GABA in convulsive and non-convulsive animal 
models of epilepsy is discussed in a review paper by 
Coenen et al. [5]. 
In the present experiment the GABA-uptake in- 
hibitor tiagabine is investigated in a rat model for 
non-convulsive epilepsy, the WAG/Rij strain of rats. 
These rats show numerous pike-wave discharges of 
the non-convulsive type and are considered as an 
animal model for generalized absence pilepsy [5,15]. 
2. Materials and methods 
Thirty-two male WAG/Rij rats were included in 
the experiment. All animals were seven months old 
and weighed 280-335 grams. Rats were chronically 
implanted with a tripolar EEG electrode set (Plastics 
One MS 333/2A) over the frontal and occipital 
cortex under deep pentobarbital nesthesia. The ani- 
mals were allowed to recover for at least one week 
after surgery. Tap water and food pellets were al- 
ways available. 
One day prior to the experimental day, the ani- 
mals were placed in a recording cage (25 cm X 35 
cm X 30 cm) and connected to recording leads for 
habituation and acquaintance. On the experimental 
day, EEG leads were connected to the polygraph and 
recordings tarted. Signals were amplified and fil- 
tered, with the high-pass filter set at 0.15 Hz and the 
low-pass filter at 70 Hz. Signals were sampled at 180 
Hz and digitized with a Codas system on a PC 
(Dataq Instruments). EEG data were stored on an 
optical disk for analysis. The EEG was recorded for 
one hour before and for two hours following drug or 
saline administration. Tiagabine was dissolved in 
saline and intraperitoneally injected in a volume of 1 
ml/kg. Animals were divided into four groups (n = 
8): a control group injected with saline, a group 
receiving 1 mg/kg tiagabine, a group receiving 3 
mg/kg tiagabine and a group receiving 10 mg/kg 
tiagabine. 
Behavioural observation took place for a period of 
30 min starting immediately after drug administra- 
tion. The observer was experienced in recording 
animal behaviour, but was not blind to the animal's 
condition. Behavioural data were stored on a portable 
Tandy computer and analysed with The Observer 
[10]. Periods of passive wakefulness were on-line 
recorded for a period of one hour directly after drug 
administration. The spectral content of the EEG dur* 
ing these periods of passive wakefulness was off-line 
established using a FFF routine (Dataq Instruments) 
and averaged for each animal [3]. The number and 
duration of spike-wave discharges in the EEG were 
separately determined in periods of 15 min. Ampli- 
tude and frequency criteria for spike-wave dis- 
charges are elaborated previously [15]. In short, a 
spike-wave discharge was identified as such if it 
included a train of sharp spikes and slow waves with 
a frequency between 7 and 11 Hz, whereas the 
minimum duration of the train was one second. 
All EEG and behavioural data were analysed with 
a one-way analysis of variance with dose as factor 
(four levels). If appropriate, Duncan's post-hoc tests 
(P  < 0.05) were used to evaluate differences be- 
tween groups. 
3. Results 
3.1. Effects of  tiagabine on spike-wave discharges 
Tiagabine appeared to have potent facilitating ef- 
fects on the number of spike-wave discharges 
(SWDs) and a clear dose-response relationship could 
be established. Effects of tiagabine on the number of 
SWDs in the cortical EEG are shown in Fig. 1. The 
group with the highest dose of tiagabine (10 mg/kg) 
has the greatest increase in the number of SWDs, 
whereas the group with the lowest dose (1 mg/kg) 
showed only a non-significant marginal increase. An 
analysis of variance showed significant differences 
between the four groups in the first (F(3,28) = 7.60, 
P < 0.001), the second (F(3,28) = 14.70, P < 
0.0005), the third (F(3,28) = 9.47, P < 0.0005), the 
fourth (F(3,28)=4.57, P<0.01)  and the fifth 
(F(3,28) = 5.92, P < 0.005) 15-min period after drug 
administration. In all these 15-min periods the num- 
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Fig. 1. Numbers of spike-wave discharges with SEMs per period 
of 15 rain, before and after liagabine administration. The arrow 
indicates injection of the drug. * : P < 0.05. 
ber of SWDs was higher for the 10 mg/kg group 
compared to the three other groups. 
Due to tiagabine administration, the SWDs also 
increased in duration and a dose-response r lation- 
ship existed for this inc:rease in duration. The effects 
of different doses of tiagabine on the mean duration 
of SWDs are shown in Fig. 2. The effects of tiagabine 
on the duration last ~dightly longer than on the 
number of SWDs. Ana]Lysis of variance showed sig- 
nificant differences between the four groups in the 
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Fig. 2. Mean durations ofsingle trains of spike-wave discharges 
with SEMs, before and after tiagabine administration. The arrow 
indicates injection of the drug. * : P < 0.05. 
first (F(3,28) = 4,49, P < 0.05), the second 
(F(3,28) - 3.94, P < 0.05), the third (F(3,28) = 
3.71, P < 0.05), the fourth (F(3,28) = 4.97, P < 
0.01), the fifth (F(3,28)= 3.69, P < 0.05) and the 
sixth (F(3,28) = 4.70, P < 0.01) 15-min period after 
drug administration. Generally, the highest dose 
group showed a prolonged uration compared to the 
lowest dose and the saline group. 
3.2. Effects of tiagabine on behaviour 
Behaviour was divided into three categories: ex- 
ploratory or voluntary behaviour (walking, rearing 
and sniffing), automatic behaviour (eating, drinking 
and grooming) and immobile or passive behaviour 
[3]. There were no significant dose effects on the 
total time and mean durations that the animals were 
engaged in each of the behavioural categories. A
marginal significant dose effect was found on the 
total time of exploratory behaviour (F(3,28) = 2.71, 
P < 0.07), but only the highest dose of tiagabine 
showed a decrease. 
3.3. Effects of tiagabine on the EEG spectrum 
Effects of tiagabine on the spectral content of the 
EEG were established on the EEG accompanying 
passive wakefulness when the animal shows immo- 
bile behaviour. Spectral analysis was based on time 
periods of minimally 60 s. In general, it appeared 
that tiagabine had little effects on the spectral EEG 
content. Only a dose effect in the beta band of 25 to 
39 Hz was found: the four groups differed in the 
power of this frequency band (F(3,27) = 4.10, P < 
0.05). Animals with doses of 3 and 10 mg/kg 
tiagabine showed more power in this band compared 
to control animals and to rats with 1 mg/kg 
tiagabine. Furthermore, animals with a dose of 3 
mg/kg had more power in this band than the ani- 
mals with a dose of 1 mg/kg tiagabine. 
3.4. Other EEG effects of tiagabine 
Besides the effects on SWDs and the spectral 
content of the EEG, tiagabine had another striking 
effect on the EEG. After administration of the two 
highest doses of tiagabine (3 and 10 mg/kg), a 
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Fig. 3. A cortical EEG recording containing a common type I spike-wave discharge (left-middle), as well as a type II spike-wave discharge 
(right). Type II discharges are mostly short-lasting and spikes have an opposite polarity as the normal type I discharges. Time and voltage 
are calibrated. 
phenomenon occurred which we originally described 
as type II SWDs [15]. These are short-lasting SWDs 
with a deviant morphology, not having a behavioural 
concomitant. In Fig. 3 an example of such a phe- 
nomenon is shown, together with a regular type I 
spike-wave discharge. No such type II phenomena 
were observed in baseline conditions, while rats in 
the 0 and 1 mg/kg groups also did not show any of 
these type II spike-wave discharges. They became 
visible during the first 15-min period after adminis- 
tration of 3 and 10 mg/kg tiagabine, and increased 
in number during the second and third 15-min 
recording period. During the following 15-rain peri- 
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Fig. 4. Number of type II spike-wave discharges with SEMs 
occurring after administration of 3 and 10 mg/kg tiagabine. No 
such phenomena occur after administration of 0 and 1 mg/kg 
tiagabine. Results are presented in periods of 15 min after drug 
administration. 
ods the number of the phenomena slowly decreased 
reaching a zero base-line value in the eighth 15-min 
period. During all periods the number of type II 
phenomena is greater for 10 mg/kg animals com- 
pared to 3 mg/kg animals, which suggests a dose- 
response relationship. Mean numbers of type II phe- 
nomena for the 3 and 10 mg/kg tiagabine groups are 
shown in Fig. 4. 
4. Discussion 
Tiagabine had effects on the number as well as on 
the duration of SWDs and both parameters increased 
as a result of drug administration. The lowest dose of 
1 mg/kg had still small effects while doses of 3 and 
10 mg/kg tiagabine show considerable actions. In 
general, little effects were seen on the spectral char- 
acteristics of the EEG. Merely the power in the beta 
range increased after tiagabine with only the two 
highest doses. No corresponding behavioural signs 
such as an increase in alertness or exploratory be- 
haviour were found. Moreover, exploratory be- 
haviour had even a slight tendency to decrease. The 
finding of an increase in power of the beta band of 
the EEG, which is not associated with parallel effects 
on behaviour such as an increase in active behaviour, 
seems contradictory. It is known, however, that cer- 
tain types of drugs produce still larger dissociating 
effects on EEG and behaviour. With benzodi- 
azepines, for example, even hypnotic and sedatory 
actions occur simultaneously with an increase in the 
power of the beta band [3]. This is known as pharma- 
A.M.L. Coenen et al. / Epilepsy Research 21 (1995) 89-94 93 
cological dissociation: a drug may have opposite 
effects on EEG and behaviour [4]. 
Next to the facilitation of SWDs, an unexpected 
effect of tiagabine was found: the appearance of 
another type of paroxysmal ctivity. These phenom- 
ena, also called type II SWDs, were earlier described 
as spontaneously occurring in WAG/Rij rats [15]. In 
the present experiment, they were clearly seen after 
administration f the two highest doses of tiagabine 
of 3 and 10 mg/kg. Th,~ dose of 1 mg/kg tiagabine 
did not produce these phenomena. From occasional 
and cortical mapping observations, it appeared that 
these type II phenomena are bilateral synchronous, 
but have a more local, occipital origin than the 
commonly found type I SWDs, which seem to be 
more generalized over the frontal cortex [14]. The 
occurrence of these still enigmatic type II paroxysms 
seems to be a process in line with the enhancement 
of the more generally occurring type I SWDs. An 
assumption is that these type II phenomena might be 
forerunners of genuine type I SWDs. However, it is 
so far not described that muscimol, another GABA- 
mimetic drug enhancing spike-wave discharges, also 
give rise to these type II SWDs. It might be that 
aggravation of type II SWDs is restricted to a spe- 
cific mode of action of the drug on the GABA-ergic 
system. 
Tiagabine is a drug which stimulates GABA-ergic 
functions in an indirect way, by inhibition of the 
re-uptake of GABA in synaptic terminals [9]. The 
facilitating effects on the non-convulsive type of 
epilepsy by GABA-stimulating drugs is already ear- 
lier described by us [12,13], as well as by others 
[7,16]. Non-convulsive discharges react in an oppo- 
site way to GABA-ergilc facilitation as convulsive or 
tonic-clonic seizures. The latter are strongly sup- 
pressed by GABA agonists and facilitated by antago- 
nists. In general, this means that the results obtained 
with tiagabine fit into this overall picture. They again 
underline that GABA i,i involved in absence pilepsy. 
Stimulation of GABA causes an increase of spike- 
wave activity, which suggests that non-convulsive 
epilepsy is associated with GABA-ergic hyperfunc- 
tion. This implies that the mechanism of action is 
different from drugs which inhibit non-convulsive 
seizures, such as the benzodiazepines. Though the 
latter drugs are gene:rally regarded as agonists at 
GABA receptors, the opposite results of the SWD- 
enhancing GABA agonists on one hand and the 
SWD-reducing benzodiazepines on the other [3] 
proves that the statement that benzodiazepines act as 
genuine GABA agonists is presumably not com- 
pletely true. 
The distinction between typical anti-convulsive 
drugs and anti-absence drugs becomes more and 
more obvious and indicates a biochemical difference 
in the regulation of systems underlying the two main 
types of epilepsy. There are more anticonvulsants 
such as diphenylhydantoin and carbamazepine, which 
also aggravate SWDs in WAG/Rij rats [12]. These 
drugs are also ineffective against absences in hu- 
mans, but are effective in tonic-clonic seizures [1,2]. 
Regarding the effectiveness of tiagabine in several 
models for convulsive pilepsy and considering the 
results presented here, tiagabine seems to belong to 
the category of anti-convulsive drugs. Tiagabine has 
been shown to be efficacious as add-on treatment in
complex partial seizures with and without secondary 
generalization (Richens et al., submitted). It should 
be worthwhile to investigate further the cognitive 
profile of tiagabine and to compare it with the 
profiles of other anti-convulsants. It is possible that 
the indirect mode of action on GABA might give 
rise to fewer adverse ffects on behaviour and cogni- 
tion than existing drugs directly modulating the 
GABA-ergic system or other currently used anticon- 
vulsants such as diphenylhydantoin and carba- 
mazepine. The choice of anti-convulsants is also 
partially based on the lack of cognitive side effects. 
In the present experiment, it is already shown that 
tiagabine showed almost no behavioural effects and 
only slight effects on the background EEG. 
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